Parati Gianfranco, Pengo Martino F, Avolio Alberto, Azizi Michel, Bothe Tomas Lucca, Burnier Michel, Cappuccio Francesco Paolo, Sierra Alejandro De La, Fava Cristiano, Gironacci Mariela M, Hoshide Satoshi, Kario Kazuomi, Kollias Anastasios, Lombardi Carolina, Maiolino Giuseppe, Maule Simona, Narkiewicz Krzysztof, Ohkubo Takayoshi, Palatini Paolo, Pepin Jean Luis, Sarafidis Pantelis, Schutte Aletta Elisabeth, Silvani Alessandro, Stergiou George, Verdecchia Paolo, Mancia Giuseppe, Bilo Grzegorz
Istituto Auxologico Italiano, IRCCS, Department of Cardiology, Ospedale San Luca.
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
J Hypertens. 2025 May 19;43(8):1296-318. doi: 10.1097/HJH.0000000000004053.
Interest in the pathophysiology, measurement, and clinical implications of nocturnal blood pressure (BP) has significantly increased due to its strong association with cardiovascular risk, and its importance was recognized by the 2023 European Society of Hypertension (ESH) guidelines. Nocturnal BP regulation is complex and multifactorial, involving sleep-wake cycle, circadian rhythms, autonomic nervous system, renin-angiotensin-aldosterone system, and renal mechanisms. 24-h ambulatory blood pressure monitoring is currently the reference method for nocturnal BP assessment. Home BP monitoring, with specially designed, validated devices with nocturnal BP measuring function, may also be used, while new cuffless and wearable technologies hold great potential but require further validation. Nocturnal BP phenotypes of clinical interest include nocturnal hypertension, increased nocturnal BP variability and altered day-night BP fluctuations. Among those, isolated nocturnal hypertension may be considered a type of masked hypertension. BP variability has prognostic relevance, as do the day-night BP changes, i.e. the nocturnal BP "dipping". Nocturnal hypertension and nondipping are particularly prevalent in individuals with autonomic neuropathies, sleep disorders (e.g., obstructive sleep apnoea), kidney disease, and metabolic or endocrine disorders, and are linked to hypertension mediated organ damage and cardiovascular risk. Therapeutic strategies targeting nocturnal BP remain debated. Chronotherapy (evening dosing of antihypertensives) has shown inconsistent results in clinical trials. Renal denervation and treatment of sleep-related breathing disorders may lower nocturnal BP and improve sleep quality. More research is needed to further clarify pathophysiology, measurement, therapeutic interventions, and overall management of nocturnal hypertension, issues on which this ESH position paper offers an in-depth review.
由于夜间血压(BP)与心血管风险密切相关,对其病理生理学、测量方法及临床意义的关注显著增加,并且其重要性在2023年欧洲高血压学会(ESH)指南中得到了认可。夜间血压调节复杂且涉及多因素,包括睡眠-觉醒周期、昼夜节律、自主神经系统、肾素-血管紧张素-醛固酮系统及肾脏机制。24小时动态血压监测是目前评估夜间血压的参考方法。家庭血压监测也可使用,采用具有夜间血压测量功能的经过专门设计和验证的设备,而新型无袖带和可穿戴技术具有很大潜力,但需要进一步验证。具有临床意义的夜间血压表型包括夜间高血压、夜间血压变异性增加和昼夜血压波动改变。其中,孤立性夜间高血压可被视为一种隐匿性高血压。血压变异性具有预后相关性,昼夜血压变化(即夜间血压“勺型”变化)也是如此。夜间高血压和非勺型血压在自主神经病变、睡眠障碍(如阻塞性睡眠呼吸暂停)、肾脏疾病以及代谢或内分泌疾病患者中尤为普遍,并且与高血压介导的器官损害和心血管风险相关。针对夜间血压的治疗策略仍存在争议。时间治疗法(晚上服用降压药)在临床试验中结果不一致。肾去神经支配和治疗与睡眠相关的呼吸障碍可能会降低夜间血压并改善睡眠质量。需要更多研究来进一步阐明夜间高血压的病理生理学、测量方法、治疗干预措施及整体管理,本ESH立场文件对这些问题进行了深入综述。